A University of New Mexico-trained doctor isn’t going to lead the U.S. Food and Drug Administration after all, after pushback from senators from both parties and some of her fellow graduates.

The White House said Tuesday it pulled the nomination of Dr. Heidi Overton to lead the federal agency — which is responsible for ensuring the safety of food, medications, cosmetics and medical devices — amid growing indications she didn’t have the votes needed to win Senate confirmation.

The move came the day before a key committee was scheduled to vote on her nomination, as Republicans race to confirm Trump’s current nominees before handing over power to Senate Democrats in January.

For Dr. Mike Winer, a family and addiction medicine physician who graduated from UNM School of Medicine’s combined Bachelor of Arts/Doctor of Medicine program in 2018, the decision to withdraw Overton’s nomination came as a relief. Overton graduated from the medical school in 2015.

“The U.S. has just lost its measles elimination status and reproductive healthcare continues to be under attack,” Winer wrote in a message to The New Mexican. “We need an F.D.A. commissioner that makes decisions grounded in science, protects children, and defends evidence-based reproductive health care — not one who will make decisions based on the current political winds or religious dogma.”

Overton, a physician and White House domestic policy adviser who grew up in Gallup, has spent most of her professional career working directly for President Donald Trump or conservative groups aligned with his agenda. She would have been tasked with stabilizing the agency after a tumultuous year under Trump’s first FDA commissioner, Dr. Marty Makary, and as Americans suffered from major food safety issues and a deadly measles outbreak.

However, Overton has faced pushback from senators and fellow UNM alumni alike, with critics questioning whether she would be willing to break with Trump and U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic, on key pharmaceuticals overseen by the FDA, including childhood vaccines and abortion drugs. More than 50 alumni of the UNM School of Medicine had in recent months signed onto a letter objecting to her nomination.

“The leadership of the FDA requires an administrator whose policy record aligns with established clinical consensus and sound regulatory science,” the letter stated. “Dr. Overton’s public policy record — particularly her documented stances challenging established reproductive health practices that are backed by decades of safety and efficacy data, her support for non-evidence-based alterations to immunization guidance, and her calls to politicize federal health agency science — diverge significantly from the evidence-based standards instilled by our shared medical education.”

Republican Sen. Bill Cassidy, a Louisiana doctor who chairs the Senate Committee on Health, Education, Labor and Pensions, said earlier in the day Tuesday he remained undecided about Overton.

Cassidy previously called Overton’s support for Trump’s plan to break up combination vaccines — including the measles, mumps and rubella shot — “almost disqualifying.” And he pressed her during a September hearing about her scientific independence and willingness to push back against Trump and Kennedy.

During that same hearing, Democratic and Republican senators alike questioned Overton’s record on mifepristone, one of two drugs typically used to end a pregnancy in the first 10 weeks. Sen. Lisa Murkowski of Alaska, one of the few Senate Republicans who supports abortion rights, said she was concerned about the possibility of the FDA changing mifepristone’s approval due to political pressure. She argued requiring an in-person doctor’s visit for the drug would cut off access for people in rural states like hers.

To win confirmation, Overton would have needed the votes of all 12 Republicans on the committee. Democrats hold 11 seats. Without support of the committee, Overton faced little chance of winning a full Senate vote on chamber floor.

Winer said he hopes federal officials will “consider what is best for our country” as they mull future candidates to lead the FDA.

Information from The Associated Press was used in this report.

Margaret O’Hara reports on issues affecting healthy communities in New Mexico. Her work is funded by a grant from Anchorum Health Foundation. Anchorum will not have any role in editorial decisions. The New Mexican and its Public Service Journalism Fund retain full editorial control. Philanthropically funded stories by The New Mexican are made available to all readers without a paywall.

Republish our articles for free, online or in print, under a Creative Commons license.

Leave a comment